微创心通-B(02160)盘中涨超9%，截至发稿，涨6.06%，报1.05港元，成交额448.37万港元。 值得注意的是，12月19日，微创医疗宣布心通收购心律的合并落地。此次并购将推动微创医疗旗下结构 性心脏病与心律管理两大核心业务板块的深度整合。随着最新整合方案的公布，意味着微创医疗将加速 构建覆盖心力衰竭全病因、全阶段、全过程的综合器械管理方案。 消息面上，微创心通的VitaFlow Liberty/自由·维心流经导管主动脉瓣及可回收系统，摩洛哥获批上市， 标志着该产品首次进入非洲市场。摩洛哥医疗器械市场对进口产品依赖度高，此次获批为该产品后续拓 展非洲其他国家奠定基础。 ...

Group 1 - The core viewpoint of the article highlights the significant stock price increase of MicroPort Cardiac Rhythm Management (02160), which rose over 9% during trading and is currently up 6.06% at HKD 1.05, with a trading volume of HKD 4.48 million [1] - MicroPort's VitaFlow Liberty aortic valve and retrieval system has received approval for sale in Morocco, marking its first entry into the African market, which is heavily reliant on imported medical devices [1] - The acquisition of Cardiac Rhythm by MicroPort Medical has been finalized, which will enhance the integration of its structural heart disease and cardiac rhythm management business segments, accelerating the development of a comprehensive device management solution for heart failure [1]